Finoriq research workspace
MADRIGAL PHARMACEUTICALS, INC. (MDGL) SEC Filings & Filing Highlights
MADRIGAL PHARMACEUTICALS, INC. offers Rezdiffra, a liver-directed thyroid hormone receptor beta. Review MDGL SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Company
- MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Ticker
- MDGL
- Market Cap
- $12.4B
- Latest Price
- $536.86
- Industry
- Biotech & Pharma
MADRIGAL PHARMACEUTICALS, INC. (MDGL) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
| Event | Form | Date |
|---|---|---|
| Broker Non-VotesOn June 17, 2026, the Company held its Annual Meeting. As of April 23, 2026, the record date for the Annual Meeting, 23,055,522 shares of t... | 8-K5.07 | 2026-06-17 |
| 2026 Stock Plan On June 17, 2026, at the annual meeting of stockholders (the "Annual Meeting")...2026 Stock Plan On June 17, 2026, at the annual meeting of stockholders (the "Annual Meeting") of Madrigal Pharmaceuticals, Inc. (the "Comp... | 8-K5.02 | 2026-06-17 |
| Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Up...Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates | 8-K2.02 | 2026-05-06 |
| On April 22, 2026, the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the...On April 22, 2026, the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”) completed a process to reclassify... | 8-K5.02 | 2026-04-28 |
| Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial ResultsMadrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results | 8-K2.02 | 2026-02-19 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.